News | Amgen
Amgen Foundation Awards and Accolades How We Operate
Newsroom - Amgen
Amgen is committed to providing the media with timely and accurate information. This section offers key resources for journalists, editors and other media professionals. Latest Press Releases
Press Releases - Amgen Inc.
Oct 24, 2024 · news release 06.05.2024. amgen announces positive results for phase 3 registrational trial evaluating uplizna® (inebilizumab-cdon) for treatment of immunoglobulin g4-related disease (igg4-rd)
FDA APPROVES IMDELLTRA™ (TARLATAMAB-DLLE), THE FIRST …
May 16, 2024 · Amgen remains committed to progressing multiple BiTE molecules across a broad range of hematologic and solid tumor malignancies, paving the way for additional applications in more tumor types. Amgen is further investigating BiTE technology
AMGEN COMPLETES ACQUISITION OF HORIZON THERAPEUTICS …
Oct 6, 2023 · Advances Amgen's Mission to Serve Patients With First-in-Class Rare Disease Medicines. THOUSAND OAKS, Calif., Oct. 6, 2023 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that it has completed its acquisition of Horizon Therapeutics plc for $116.50 per share in cash, representing a transaction equity value of approximately $27.8 billion.
AMGEN TO ACQUIRE CHEMOCENTRYX FOR $4 BILLION IN CASH
Aug 4, 2022 · THOUSAND OAKS, Calif. and SAN CARLOS, Calif., Aug. 4, 2022 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and ChemoCentryx, Inc., (NASDAQ: CCXI), a biopharmaceutical company focused on orally administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer, today announced that the companies have entered into a definitive ...
AMGEN SUCCESSFULLY COMPLETES ACQUISITION OF …
THOUSAND OAKS, Calif., Oct. 20, 2022 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that it has successfully completed its previously announced acquisition of ChemoCentryx, Inc. (NASDAQ: CCXI), a biopharmaceutical company focused on orally administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer, for …
AMGEN OUTLINES GROWTH STRATEGY THROUGH 2030 AT …
Feb 8, 2022 · Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average and is also part of the Nasdaq-100 index. In 2021, Amgen was named one of the 25 World's Best Workplaces™ by Fortune and Great Place to Work™ and one of the 100 most sustainable companies in the world by Barron's.
AMGEN PRESENTS NEW AMG 133 PHASE 1 CLINICAL DATA AT …
Dec 1, 2022 · amgen presents new amg 133 phase 1 clinical data at wcirdc 2022 AMG 133 is a First-in-Class Investigational Bispecific Molecule That Activates GLP-1R and Inhibits GIPR Phase 1 Results Showed up to 14.5% Reduction in Body Weight at the Highest Dose After 12 Weeks
AMGEN REPORTS THIRD QUARTER FINANCIAL RESULTS
Oct 31, 2023 · "With the completion of the Horizon acquisition, Amgen has added rare disease medicines that fit well with our broad innovative portfolio." Key results include: Total revenues increased 4% to $6.9 billion in comparison to the third quarter of 2022, resulting from a 5% increase in product sales.